Evidence map›Paper›PMID 34266995›Full record

ArticleRNA (New York, N.Y.)2021

Genome-wide analyses of XRN1-sensitive targets in osteosarcoma cells identify disease-relevant transcripts containing G-rich motifs.

Amy L Pashler, Benjamin P Towler, Christopher I Jones, Hope J Haime, Tom Burgess, Sarah F Newbury

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RNA (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Drug Discovery from Gene Expression/Gene Regulation.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Amy L PashlerBrighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PS, United Kingdom.
Benjamin P TowlerBrighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PS, United Kingdom.
Christopher I JonesBrighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PS, United Kingdom.
Hope J HaimeBrighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PS, United Kingdom.
Tom BurgessBrighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PS, United Kingdom.
Sarah F NewburyBrighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PS, United Kingdom.
Brighton and Sussex Medical School · GB

Funding

Biotechnology and Biological Sciences Research Council BB/P021042/1
6 · The paper itself

Abstract

XRN1 is a highly conserved exoribonuclease which degrades uncapped RNAs in a 5'-3' direction. Degradation of RNAs by XRN1 is important in many cellular and developmental processes and is relevant to human disease. Studies in

Indexed as

Bone NeoplasmsCell Line, TumorChildComputational BiologyExoribonucleasesGene Expression Regulation, NeoplasticGene Knockdown TechniquesGenome-Wide Association StudyHumansMicrotubule-Associated ProteinsMolecular Sequence AnnotationNucleotide MotifsOsteosarcomaRNA, Long NoncodingRNA, MessengerRNA, NeoplasmExoribonucleasesHOTAIR long untranslated RNA, humanMicrotubule-Associated ProteinsRNA, Long NoncodingRNA, MessengerRNA, NeoplasmXRN1 protein, humanEwing sarcomalncRNAsRNA degradationRNA-seqXRN1

Identifiers

PMID34266995
PMCPMC8457002
OpenAlexW3181139400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.